Metabomed

Target-inhibiting Anticancer Drugs

Health Tech & Life Sciences
Non Active, May 2024 ceased to operate
Series A Yavne, Israel Founded 2013
LinkedIn
Last updated 2026-06-18
Total raised
$30.5M
Last: 2022-04
Stage
Series A
Founded
2013
Headcount
5
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences

About

Metabomed is a drug-discovery company in the field of cancer metabolism, with a proprietary target-identification platform based on computational biology and metabolomics. The company focuses on developing drugs that inhibit targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells. Using this target-inhibiting strategy, Metabomed intends to develop more selective, highly focused anticancer drugs with the ability to kill cancer cells without harming normal cells.

Funding history · 4 rounds · $30.5M total

Q&A

What is Metabomed's current operational status?
Metabomed is currently inactive and ceased to operate in May 2024.
What is Metabomed's primary focus?
Metabomed is a drug-discovery company focused on cancer metabolism, developing drugs that inhibit targets forming a synthetic lethal gene pair with metabolic genes inactivated in cancer cells.
When was Metabomed founded?
Metabomed was founded in October 2013.
How much funding has Metabomed raised in total?
Metabomed has raised a total of $30,500,000 USD.
Which investors participated in Metabomed's April 2016 funding round?
In April 2016, Metabomed received funding from M Ventures and Pontifax.
Which investor led Metabomed's December 2019 funding round?
Metabomed's December 2019 funding round was led by Yonjin Ventures.
Where is Metabomed's headquarters located?
Metabomed's headquarters is located in Yavne, Israel.

Team · 2

Founder · Co-founder
LinkedIn ↗
Founder · Co-founder (No longer with the company)
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCellsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

pharma-companiestargeted-therapyoncologybiotechnologybiopharmaceuticalcancerdrug-discoverygenomics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/9341600

Identifiers & details

Founded2013-10
Employees (exact)5
OfficesCambridge
Status reasonNon Active, May 2024 ceased to operate